Kengreal
Chemical Name | cangrelor |
Dosage Form | Injection (intravenous; 50 mg/ 10 mL) |
Drug Class | Inhibitors |
System | Cardiovascular |
Company | Chiesi USA Inc |
Approval Year | 2015 |
Indication
- Indicated as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.